4.3 Article

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer

期刊

ONCOTARGET
卷 8, 期 42, 页码 71447-71455

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.16169

关键词

prostate cancer; circulating tumor cells; androgen receptor; metastases; metastatic castration resistant prostate cancer

资金

  1. NIH through OHSU-Knight Cancer Institute [R01 CA169172, P30 CA069533, P30 CA069533 13S5]
  2. Pacific Northwest Prostate Cancer SPORE/NCI [P50 CA097186]
  3. Stand Up to Cancer - Prostate Cancer Foundation - Prostate Dream Team Translational Cancer Research Grant [SU2C-AACR-DT0409]
  4. Movember Foundation
  5. Entertainment Industry Foundation [7465sc]

向作者/读者索取更多资源

Increased AR activity has been shown to be preserved in spatially distinct metastatic tumors from the same patient suggesting the requirement for lineage-specific dependencies for metastatic castration resistant prostate cancer (mCRPC). Amplification of the AR gene is a common mechanism by which mCRPC increase AR activity. To determine whether AR amplification in circulating tumor cells (CTC) could complement metastatic tissue biopsies in men undergoing treatment for mCRPC, we developed a novel two-step assay to isolate CTCs and subsequently analyzed AR amplification status in CTCs and matched biopsy tissue from the same patient by fluorescence in situ hybridization (FISH). AR gene status in CTCs showed strong concordance with AR gene status in matched tissue samples in 24 of 25 patients (Correlation: 96%; Kappa: 0.83; Sensitivity: 100%, Specificity: 83%). Our work demonstrates that AR amplification is conserved between CTCs and biopsies and that CTCs can serve as non-invasive surrogate to document AR amplification in mCRPC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biochemistry & Molecular Biology

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

Orit Rozenblatt-Rosen, Aviv Regev, Philipp Oberdoerffer, Tal Nawy, Anna Hupalowska, Jennifer E. Rood, Orr Ashenberg, Ethan Cerami, Robert J. Coffey, Emek Demir, Li Ding, Edward D. Esplin, James M. Ford, Jeremy Goecks, Sharmistha Ghosh, Joe W. Gray, Justin Guinney, Sean E. Hanlon, Shannon K. Hughes, E. Shelley Hwang, Christine A. Iacobuzio-Donahue, Judit Jane-Valbuena, Bruce E. Johnson, Ken S. Lau, Tracy Lively, Sarah A. Mazzilli, Dana Pe'er, Sandro Santagata, Alex K. Shalek, Denis Schapiro, Michael P. Snyder, Peter K. Sorger, Avrum E. Spira, Sudhir Srivastava, Kai Tan, Robert B. West, Elizabeth H. Williams

Article Multidisciplinary Sciences

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

Joshi J. Alumkal, Duanchen Sun, Eric Lu, Tomasz M. Beer, George V. Thomas, Emile Latour, Rahul Aggarwal, Jeremy Cetnar, Charles J. Ryan, Shaadi Tabatabaei, Shawna Bailey, Claire B. Turina, David A. Quigley, Xiangnan Guan, Adam Foye, Jack F. Youngren, Joshua Urrutia, Jiaoti Huang, Alana S. Weinstein, Verena Friedl, Matthew Rettig, Robert E. Reiter, Daniel E. Spratt, Martin Gleave, Christopher P. Evans, Joshua M. Stuart, Yiyi Chen, Felix Y. Feng, Eric J. Small, Owen N. Witte, Zheng Xia

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Oncology

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

Xiangnan Guan, Duanchen Sun, Eric Lu, Joshua A. Urrutia, Robert Evan Reiter, Matthew Rettig, Christopher P. Evans, Primo Lara, Martin Gleave, Tomasz M. Beer, George Thomas, Jiaoti Huang, Rahul R. Aggarwal, David A. Quigley, Adam Foye, William S. Chen, Jack Youngren, Alana S. Weinstein, Joshua M. Stuart, Felix Y. Feng, Eric J. Small, Zheng Xia, Joshi J. Alumkal

CLINICAL CANCER RESEARCH (2020)

Article Genetics & Heredity

The DNA methylation landscape of advanced prostate cancer

Shuang G. Zhao, William S. Chen, Haolong Li, Adam Foye, Meng Zhang, Martin Sjostrom, Rahul Aggarwal, Denise Playdle, Arnold Liao, Joshi J. Alumkal, Rajdeep Das, Jonathan Chou, Junjie T. Hua, Travis J. Barnard, Adina M. Bailey, Eric D. Chow, Marc D. Perry, Ha X. Dang, Rendong Yang, Ruhollah Moussavi-Baygi, Li Zhang, Mohammed Alshalalfa, S. Laura Chang, Kathleen E. Houlahan, Yu-Jia Shiah, Tomasz M. Beer, George Thomas, Kim N. Chi, Martin Gleave, Amina Zoubeidi, Robert E. Reiter, Matthew B. Rettig, Owen Witte, M. Yvonne Kim, Lawrence Fong, Daniel E. Spratt, Todd M. Morgan, Rohit Bose, Franklin W. Huang, Hui Li, Lisa Chesner, Tanushree Shenoy, Hani Goodarzi, Irfan A. Asangani, Shahneen Sandhu, Joshua M. Lang, Nupam P. Mahajan, Primo N. Lara, Christopher P. Evans, Phillip Febbo, Serafim Batzoglou, Karen E. Knudsen, Housheng H. He, Jiaoti Huang, Wilbert Zwart, Joseph F. Costello, Jianhua Luo, Scott A. Tomlins, Alexander W. Wyatt, Scott M. Dehm, Alan Ashworth, Luke A. Gilbert, Paul C. Boutros, Kyle Farh, Arul M. Chinnaiyan, Christopher A. Maher, Eric J. Small, David A. Quigley, Felix Y. Feng

NATURE GENETICS (2020)

Article Oncology

Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth

Shinji Iizuka, Manuela Quintavalle, Jose C. Navarro, Kyle P. Gribbin, Robert J. Ardecky, Matthew M. Abelman, Chen-Ting Ma, Eduard Sergienko, Fu-Yue Zeng, Ian Pass, George Thomas, Shannon K. McWeeney, Christian A. Hassig, Anthony B. Pinkerton, Sara A. Courtneidge

Summary: In this study, TAO3 was identified as a key regulator of invadopodia formation and function through high-content screening, highlighting its potential as a therapeutic target for invasive cancers.

CANCER RESEARCH (2021)

Article Oncology

Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics

Allen Li, Jamie M. Keck, Swapnil Parmar, Janice Patterson, Marilyne Labrie, Allison L. Creason, Brett E. Johnson, Molly Downey, George Thomas, Carol Beadling, Laura M. Heiser, Annette Kolodzie, Alexander R. Guimaraes, Christopher L. Corless, Joe W. Gray, Gordon B. Mills, Raymond C. Bergan, Zahi I. Mitri

Summary: The study describes an integrative approach to understanding the clinical significance of heterogeneity in breast cancer between metastatic lesions using multi-omic analyses of serial biopsies, aiming to improve cancer management. The researchers found remarkable heterogeneity among metastatic lesions in patients with metastatic breast cancer, resulting in discordance in receptor status and genomic alterations and mixed treatment responses.

NPJ PRECISION ONCOLOGY (2021)

Article Multidisciplinary Sciences

Epigenetic loss of heterogeneity from low to high grade localized prostate tumours

Sebnem Ece Eksi, Alex Chitsazan, Zeynep Sayar, George Thomas, Andrew J. Fields, Ryan P. Kopp, Paul T. Spellman, Andrew C. Adey

Summary: High tumor heterogeneity makes it difficult to identify molecular subtypes in prostate cancer. Here, the authors integrate single-cell chromatin accessibility data with multiplex imaging to reveal distinct chromatin features and transcription factor binding signatures in high- and low-grade prostate tumors.

NATURE COMMUNICATIONS (2021)

Article Multidisciplinary Sciences

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Xiangnan Guan, Fanny Polesso, Chaojie Wang, Archana Sehrawat, Reed M. Hawkins, Susan E. Murray, George Thomas, Breanna Caruso, Reid F. Thompson, Mary A. Wood, Christina Hipfinger, Scott A. Hammond, Julie N. Graff, Zheng Xia, Amy E. Moran

Summary: Immune checkpoint blockade has revolutionized oncology by inducing durable anti-tumour immunity. In advanced prostate cancer patients, immunotherapy treatments have largely failed. However, inhibiting androgen receptor activity can increase the sensitivity of tumor-bearing hosts to checkpoint blockade therapy by enhancing CD8 T cell function and improving responsiveness to PD-1 targeted therapy.

NATURE (2022)

Article Biochemical Research Methods

In-Depth Mass Spectrometry-Based Proteomics of Formalin-Fixed, Paraffin-Embedded Tissues with a Spatial Resolution of 50-200 μm

Andikan J. Nwosu, Santosh A. Misal, Thy Truong, Richard H. Carson, Kei G. Webber, Nathaniel B. Axtell, Yiran Liang, S. Madisyn Johnston, Kenneth L. Virgin, Ethan G. Smith, George Thomas, Terry Morgan, John C. Price, Ryan T. Kelly

Summary: This study modified a sample processing workflow to extract proteins from FFPE tissues and analyze protein expression. By optimizing the extraction conditions, a high-confidence proteome was obtained, and the protein coverage for FFPE tissues reached 88% compared to frozen tissues.

JOURNAL OF PROTEOME RESEARCH (2022)

Article Oncology

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Martin Sjostrom, Shuang G. Zhao, Samuel Levy, Meng Zhang, Yuhong Ning, Raunak Shrestha, Arian Lundberg, Cameron Herberts, Adam Foye, Rahul Aggarwal, Junjie T. Hua, Haolong Li, Anna Bergamaschi, Corinne Maurice-Dror, Ashutosh Maheshwari, Sujun Chen, Sarah W. S. Ng, Wenbin Ye, Jessica Petricca, Michael Fraser, Lisa Chesner, Marc D. Perry, Thaidy Moreno-Rodriguez, William S. Chen, Joshi J. Alumkal, Jonathan Chou, Alicia K. Morgans, Tomasz M. Beer, George Thomas, Martin Gleave, Paul Lloyd, Tierney Phillips, Erin McCarthy, Michael C. Haffner, Amina Zoubeidi, Matti Annala, Robert E. Reiter, Matthew B. Rettig, Owen N. Witte, Lawrence Fong, Rohit Bose, Franklin W. Huang, Jianhua Luo, Anders Bjartell, Joshua M. Lang, Nupam P. Mahajan, Primo N. Lara, Christopher P. Evans, Phuoc T. Tran, Edwin M. Posadas, Chuan He, Xiao-Long Cui, Jiaoti Huang, Wilbert Zwart, Luke A. Gilbert, Christopher A. Maher, Paul C. Boutros, Kim N. Chi, Alan Ashworth, Eric J. Small, Housheng H. He, Alexander W. Wyatt, David A. Quigley, Felix Y. Feng

Summary: This study integrates whole-genome 5hmC, DNA, 5mC, and transcriptome sequencing to investigate prostate cancer. The results show that 5hmC marks activation of cancer drivers and downstream targets, and reveal altered cell states throughout the disease course. Additionally, 5hmC sequencing of cell-free DNA proves useful as a prognostic biomarker for identifying an aggressive subtype of prostate cancer.

CANCER RESEARCH (2022)

Article Multidisciplinary Sciences

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

Thomas C. Westbrook, Xiangnan Guan, Eva Rodansky, Diana Flores, Chia Jen Liu, Aaron M. Udager, Radhika A. Patel, Michael C. Haffner, Ya-Mei Hu, Duanchen Sun, Tomasz M. Beer, Adam Foye, Rahul Aggarwal, David A. Quigley, Jack F. Youngren, Charles J. Ryan, Martin Gleave, Yuzhuo Wang, Jiaoti Huang, Ilsa Coleman, Colm Morrissey, Peter S. Nelson, Christopher P. Evans, Primo Lara, Robert E. Reiter, Owen Witte, Matthew Rettig, Christopher K. Wong, Alana S. Weinstein, Vlado Uzunangelov, Josh M. Stuart, George Thomas, Felix Y. Feng, Eric J. Small, Joel A. Yates, Zheng Xia, Joshi J. Alumkal

Summary: This study analyzed the transcriptomes of patient tumor biopsies before and during enzalutamide treatment, and identified a gene expression program associated with lineage plasticity risk and poor outcomes. The findings suggest that tumors harboring this gene expression program may be at particular risk for resistance mediated by lineage plasticity.

NATURE COMMUNICATIONS (2022)

Meeting Abstract Oncology

Transcriptional profiling of matched biopsies reveals molecular determinants of enzalutamide resistance.

Thomas Westbrook, Xiangnan Guan, Aaron M. Udager, Michael Haffner, Tomasz M. Beer, Rahul Raj Aggarwal, Charles J. Ryan, Martin Gleave, Jiaoti Huang, Christopher P. Evans, Robert Evan Reiter, Owen Witte, Matthew Rettig, Josh Stuart, George V. Thomas, Felix Y. Feng, Eric Jay Small, Joel Yates, Zheng Xia, Joshi J. Alumkal

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Automated nerve identification in histopathology slides enables comprehensive analysis of innervation in cancer and tumor neurobiology

Alison R. Miller, Daniel Krasnonosenkikh, Monica Thanawala, Kai Chih Huang, George V. Thomas, Alexandra B. Lantermann, Hongyue Dai, Masoud Sadaghiani, John A. Wagner, Pearl Huang

MOLECULAR CANCER THERAPEUTICS (2021)

Meeting Abstract Oncology

SMMART Program: A multi-omics tumor board with a focus on breast cancer.

Ben L. Kong, Brett E. Johnson, Jamie M. Keck, Souraya Mitri, Patrick Leyshock, Jayne M. Stommel, Kiara Siex, Marlana Klinger, Christina L. Zheng, Rochelle Williams-Belizaire, Shannon McWeeney, Jeremy Goecks, Annette Kolodzie, Alexander R. Guimaraes, George V. Thomas, Christopher L. Corless, Zahi I. Mitri, Joe W. Gray, Gordon B. Mills, Raymond C. Bergan

CANCER RESEARCH (2021)

Article Cell Biology

Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma

Hui-wen Lue, Daniel S. Derrick, Soumya Rao, Ahna Van Gaest, Larry Cheng, Jennifer Podolak, Samantha Lawson, Changhui Xue, Devin Garg, Ralph I. I. I. I. I. I. White, Christopher W. Ryan, Justin M. Drake, Anna Ritz, Laura M. Heiser, George Thomas

Summary: The combination therapy of cabozantinib and dasatinib shows promising efficacy in treating advanced NCCRCC by synergistically reducing cell viability through downregulation of the MAPK-ERK signaling pathway, leading to tumor regression. Additionally, the addition of a MEK inhibitor enhances the efficacy of the combination treatment.

CELL REPORTS MEDICINE (2021)

暂无数据